Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K W Johnson

Showing results (71-80 of 73) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 73 results.
Osteoarthritis and Cartilage|February 11, 2014
Development of a novel antibody to calcitonin gene-related peptide for the treatment of osteoarthritis-related painR J Benschop, E C Collins, R J Darling, et al.
Neuroscience|September 22, 2014
Activation of adult rat CNS endothelial cells by opioid-induced toll-like receptor 4 (TLR4) signaling induces proinflammatory, biochemical, morphological, and behavioral sequelaeP M Grace, K M Ramos, K M Rodgers, et al.
Journal of Medicinal Chemistry|February 2, 1996
3-Aryl-1,2-diacetamidopropane derivatives as novel and potent NK-1 receptor antagonistsP A Hipskind, J J Howbert, R F Bruns, et al.
Pageof 8

Showing results (71-80 of 73) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 73 results.
Osteoarthritis and Cartilage|February 11, 2014
Development of a novel antibody to calcitonin gene-related peptide for the treatment of osteoarthritis-related painR J Benschop, E C Collins, R J Darling, et al.
Neuroscience|September 22, 2014
Activation of adult rat CNS endothelial cells by opioid-induced toll-like receptor 4 (TLR4) signaling induces proinflammatory, biochemical, morphological, and behavioral sequelaeP M Grace, K M Ramos, K M Rodgers, et al.
Journal of Medicinal Chemistry|February 2, 1996
3-Aryl-1,2-diacetamidopropane derivatives as novel and potent NK-1 receptor antagonistsP A Hipskind, J J Howbert, R F Bruns, et al.
Pageof 8